ePoster listing and sessions

Topic: ESOPRS 2021 ePoster sessions
Time: Sep 17, 2021 16:00 Amsterdam, Berlin, Rome, Stockholm, Vienna, 15:00 London

The zoom session will be a MEETING. Please turn off your camera and mic, unless prompted by the moderators during Q&A. When you enter the meeting there will be 2 BREAKOUT ROOMS. Please choose the appropriate room to join once you have joined the meeting.

The link details are below (you need to be logged in)

You are currently not logged in.
If you have an account on this website please login to your account. Not registered yet? Signup here

(plain text version here)

Back to previous page

Orbital Mucormycosis associated with SARS/CoV-2 Infection

Author: Farzad Pakdel
ePoster Number: 219


We faced a surge in incidence of mucormycosis during COVID-19 pandemic among patients with SARS/CoV-2 Infection. We aim to report clinical features, contributing factors and outcome among patients with COVID-19-associated mucormycosis (CAM).


This was a prospective multicenter study on patients with biopsy proven sinu-orbital mucormycosis among patients with RT-PCR confirmed COVID-19 from April 2020 to September 2020 during COVID-19 Pandemic. Demographics, time interval between COVID-19 disease and mucormycosis, underlying systemic diseases, clinical features, course of disease and outcome were collected and analyzed.


Fifteen patients with COVID-19 and rhino-orbital mucormycosis were included. Mean age of patients was 51.73±14.72 years. Sixty-six percent of patients were male. The mean interval time between COVID 19 disease and mucormycosis was seven days (range: 1-37 days). Most patients had advanced mucormycosis at admission. The most common presentation was orbital apex syndrome (73%). Eight (53%) patients had cavernous sinus thrombosis. Among patients 13 (86%) had diabetes mellitus, seven (46.6 %) had received intravenous corticosteroid. Seven (47%) patients died from mucormycosis. Six (40%) received combined anti-fungal therapy and five patients (33%) underwent orbital exenteration. None of patients that received combined anti-fungal therapy died.


Findings of this study showed that clinicians should be cautious about mucormycosis during the first two weeks after COVID 19 in high-risk patients. CAM may be more advanced and aggressive course. Poor control of diabetes mellitus and ,corticosteroid therapy and severe pulmonary involvement during COVID-19 seem important underlying predisposing factors.

Additional Authors

First nameLast nameBase Hospital / Institution
MohammadrezaSalehiEmam Hospital/Tehran University of Medical Sciences
KazemAhmadikiaDepartment of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences
AzinTabariEmam Hospital/Tehran University of Medical Sciences
RozitaJafariEmamhossein Hospital/Shahisbeheshti University of Medical Sciences
SadeghKhodavaisy2Department of infectious diseases and Tropical Medicine, Imam Khomeini Hospital complex, Tehran University of Medical Sciences

Abstract ID: 21-109